Skip to main content
Figure 2 | BMC Complementary and Alternative Medicine

Figure 2

From: Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway

Figure 2

Effects of inhibitors on Angelica Sinensis (AS)-induced hypertrophy after 72 h treatment. C2C12 myotubes were treated for 72 h with: 100 nM wortmannin in DMEM, an inhibitor of PI3K (A); 10 ng/mL rapamycin in DMEM, an inhibitor of mTOR (B). The vertical axes indicated relative myotube diameter normalized to the mean diameter of non-AS supplements (error bars: SD). Black bars represented myotubes without inhibitors, and white bars were myotubes with inhibitors, respectively. NON, non-AS supplements, 2% HS/DMEM; IGF-1, Insulin growth factor 1 stimulation, 10 ng/mL of IGF-1 in 2% HS/DMEM; AS, Angelica Sinensis treatment, 10 ng/mL of AS in 2% HS/DMEM. (NON, n = 103; IGF-1, n = 92; AS, n = 91; n-value represented the myotube numbers from image). Data were analyzed with two-way ANOVA. *Significantly different compared with the NON without inhibitor: wortmannin (A) and rapamycin (B) (Scheffe’s post hoc analysis, P < 0.05). #Significant inhibitor effect in the same group (Scheffe’s post hoc analysis, P < 0.05).

Back to article page
\